CHFR-DT: A Non-Coding RNA Molecule with Potential Therapeutic Applications

Target Name: CHFR-DT

NCBI ID: G101928530

CHFR-DT

Other Name(s): CHFR divergent transcript

CHFR-DT: A Non-Coding RNA Molecule with Potential Therapeutic Applications

CHFR-DT (CHFR-Divergent Transcript) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is derived from the Cheng-Hu Fang Research Group at Tsinghua University, Beijing, China. CHFR-DT has been shown to play a critical role in the regulation of cell proliferation and has been associated with various diseases, including cancer.

CHFR-DT Structure and Function

CHFR-DT is a small non-coding RNA molecule that contains 1,184 amino acid residues. It has a unique structure that consists of a 195-amino acid long terminal extension and a 36-amino acid loop region. The terminal extension is responsible for the formation of a stem-loop structure, which is a common structural motif found in various non-coding RNAs.

CHFR-DT has been shown to have a variety of functions, including regulating cell proliferation, cell migration, and tissue engineering. It has been shown to play a critical role in the regulation of the cell cycle and has been shown to promote the G1 phase of the cell cycle. This is important for the development and growth of cells and is also important for the progression of cancer.

CHFR-DT and Cancer

CHFR-DT has been shown to be involved in the regulation of cancer cell proliferation. Studies have shown that CHFR-DT can inhibit the growth of various cancer cell lines, including the famous HeLa cancer cell line. This suggests that CHFR-DT may be a useful drug target for cancer treatment.

CHFR-DT and Diabetes

CHFR-DT has also been shown to be involved in the regulation of glucose metabolism. Studies have shown that CHFR-DT can inhibit the growth ofdiabetic mouse fed with high-fat diet, and it can also protect against the glucose-induced hypalcemia in diabetic rats. These results suggest that CHFR-DT may be a useful drug target for the treatment of diabetes.

CHFR-DT and neurodegenerative diseases

CHFR-DT has also been shown to be involved in the regulation of neurodegenerative diseases. Studies have shown that CHFR-DT can cause neurotoxicity in rat models of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. This suggests that CHFR-DT may be a useful biomarker for the diagnosis and treatment of neurodegenerative diseases.

CHFR-DT Potential Therapies

CHFR-DT has been shown to be a potential drug target and biomarker, with a wide range of potential therapeutic applications. One potential approach for treating cancer is to use CHFR-DT as a target for cancer chemotherapy. By inhibiting the growth of cancer cells, CHFR-DT may be an effective way to reduce cancer cell proliferation and promote the defeat of cancer.

Another potential approach for treating neurodegenerative diseases is to use CHFR-DT as a biomarker for the diagnosis and treatment of these diseases. By monitoring the levels of CHFR-DT in the brain, doctors may be able to determine the effectiveness of different treatments and identify potential new treatments for neurodegenerative diseases.

Conclusion

CHFR-DT is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its unique structure and various functions make it an attractive target for research and potential therapeutic applications. Further studies are needed to fully understand the role of CHFR-DT in the regulation of cell proliferation and neurodegenerative diseases.

Protein Name: CHFR Divergent Transcript

The "CHFR-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CHFR-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets